1. |
Polykratis A, Delbé J, Courty J, et al. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis[J]. Int J Biochem Cell Biol, 2004, 36(10):1954-1966.
|
2. |
Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts[J]. Cell Cycle, 2007, 6(23):2877-2883.
|
3. |
Papadimitriou E, Mikelis C, Lampropoulou E, et al. Roles of pleiotrophin in tumor growth and angiogenesis[J]. Eur Cytokine Netw, 2009, 20(4):180-190.
|
4. |
邢传平, 刘斌, 董亮. 免疫组织化学标记结果的判断方法[J]. 中华病理学杂志, 2001, 30(4):318.
|
5. |
Guo P, Huang ZL, Yu P, et al. Trends in cancer mortality in China:an update[J]. Ann Oncol, 2012, 23(10):2755-2762.
|
6. |
李宏伟, 张海, 许若飞, 等. 结直肠腺癌中Galectin-3、Fascin-1和β-catenin蛋白表达与其临床病理特征的关系[J]. 中国普外基础与临床杂志, 2012, 19(4):410-415.
|
7. |
Deuel TF, Zhang N, Yeh HJ, et al. Pleiotrophin:a cytokine with diverse functions and a novel signaling pathway[J]. Arch Biochem Biophys, 2002, 397(2):162-171.
|
8. |
Klomp HJ, Zernial O, Flachmann S, et al. Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients[J]. Clin Cancer Res, 2002, 8(3):823-827.
|
9. |
Mikelis C, Koutsioumpa M, Papadimitriou E. Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer[J]. Recent Pat Anticancer Drug Discov, 2007, 2(2):175-186.
|
10. |
余勇, 施敏骅, 徐迅, 等. 多效蛋白基因沉默对小细胞肺癌H446细胞中部分肿瘤生长相关基因表达的影响[J]. 中华肿瘤杂志, 2010, 32(6):405-409.
|
11. |
Yao J, Ma Q, Wang L, et al. Pleiotrophin expression in human pancreatic cancer and its correlation with clinicopathological features, perineural invasion, and prognosis[J]. Dig Dis Sci, 2009, 54(4):895-901.
|
12. |
Tsirmoula S, Dimas K, Hatziapostolou M, et al. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo[J]. Cancer Sci, 2012, 103(10):1826-1832.
|
13. |
Jäger R, List B, Knabbe C, et al. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancerpatients[J]. Br J Cancer, 2002, 86(6):858-863.
|
14. |
Wu H, Barusevicius A, Babb J, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastaticpotential[J]. J Cutan Pathol, 2005, 32(2):125-130.
|
15. |
李宏伟, 王铁山, 黄勇, 等. 结直肠腺癌中Fascin-1蛋白表达与其临床病理特征的关系[J]. 中国普外基础与临床杂志, 2010, 17(4):362-364.
|
16. |
Chung HW, Wen Y, Choi EA, et al. Pleiotrophin (PTN) and midkine (Mk) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis[J]. Mol Hum Reprod, 2002, 8(4):350-355.
|
17. |
Mikelis C, Lamprou M, Koutsioumpa M, et al. A peptide corres-ponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro[J]. J Cell Biochem, 2011, 112(6):1532-1543.
|
18. |
Orr B, Vanpoucke G, Grace OC, et al. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia[J]. Prostate, 2011, 71(3):305-317.
|
19. |
Diamantopoulou Z, Bermek O, Polykratis A, et al. A pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPβ/ζ[J]. Mol Cancer, 2010, 9:224.
|
20. |
Yao J, Zhang M, Ma QY, et al. PAd-shRNA-PTN reduces pleiotrophin of pancreatic cancer cells and inhibits neurite outgrowth of DRG[J]. World J Gastroenterol, 2011, 17(21):2667-2673.
|
21. |
梁忆波, 崔琳, 于建宪, 等. 组织芯片检测结直肠癌中HGF/c-met的表达及其与肿瘤血管生成的关系[J]. 中国普外基础与临床杂志, 2010, 17(7):713-718.
|